专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09829494B2 Methods of treatment using ADM antibodies 有权
公开(公告)号：US09829494B2
公开(公告)日：2017-11-28
申请号：US12095675
申请日：2005-12-01
申请人： Andreas Bergmann , Joachim Struck , Nils G. Morgenthaler
发明人： Andreas Bergmann , Joachim Struck , Nils G. Morgenthaler
IPC分类号： G01N33/53 , A61K39/395 , G01N33/74 , C07K16/26
CPC分类号： G01N33/74 , A61K39/3955 , C07K16/26
摘要： The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.

2. 发明授权

US09012151B2 Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin 有权
标题翻译：使用前肾上腺髓质素的后期心肌梗死患者的不良事件的诊断方法和风险分层
公开(公告)号：US09012151B2
公开(公告)日：2015-04-21
申请号：US11937061
申请日：2007-11-08
申请人： Leong Loke Ng , Andreas Bergmann , Joachim Struck , Nils Morgenthaler , Jana Papassotiriou
发明人： Leong Loke Ng , Andreas Bergmann , Joachim Struck , Nils Morgenthaler , Jana Papassotiriou
IPC分类号： G01N33/53 , A61K39/00 , A61K39/395 , G01N33/563 , A61K38/00 , G01N33/68 , G01N33/74
CPC分类号： G01N33/74 , G01N33/6893 , G01N2800/324 , G01N2800/50
摘要： The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.
摘要翻译：本发明提供了通过proADM诊断和危及心肌梗塞后不良事件分层的方法，由此确定标记物前肾上腺髓质素或其部分序列或其片段或包含在标记物组合中（面板，簇）在心肌梗死后患者中进行。本发明还提供了用于执行本发明方法的诊断装置和试剂盒。

3. 发明授权

US08735079B2 Method for risk stratification in stable coronary artery disease 有权
标题翻译：稳定性冠状动脉疾病风险分层方法
公开(公告)号：US08735079B2
公开(公告)日：2014-05-27
申请号：US12671823
申请日：2008-08-01
申请人： Andreas Bergmann , Joachim Struck , Nils G. Morgenthaler , Jana Papassotiriou , Stefan Blankenberg , Karl Lackner , Hans Rupprecht , Christoph Bickel
发明人： Andreas Bergmann , Joachim Struck , Nils G. Morgenthaler , Jana Papassotiriou , Stefan Blankenberg , Karl Lackner , Hans Rupprecht , Christoph Bickel
IPC分类号： G01N33/53
CPC分类号： G01N33/74 , G01N33/53 , G01N2333/585 , G01N2800/323 , G01N2800/324 , G01N2800/50 , G01N2800/54
摘要： An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations.
摘要翻译：公开了用于稳定动脉硬化，特别是稳定性冠状动脉疾病的患者的风险分层的体外方法，其中使用高度敏感的PCT测定在这些患者的循环中测定降钙素原的浓度，并且其中在PCT浓度范围内在健康人的典型正常范围内，定义了根据个人心脏风险区分稳定动脉硬化的个体患者群体的临界值，并且根据其各自的PCT浓度将患者分配到所述风险组之一。

4. 发明授权

US08691595B2 Method for detecting analytes 有权
标题翻译：检测分析物的方法
公开(公告)号：US08691595B2
公开(公告)日：2014-04-08
申请号：US12666024
申请日：2008-06-20
申请人： Andreas Bergmann , Joachim Struck
发明人： Andreas Bergmann , Joachim Struck
IPC分类号： G01N33/549
CPC分类号： G01N33/54306
摘要： The subject of this invention is a process for detection of analytes from biological samples comprising the following process steps: a) Preparation of a reversible binding partner 1 that is immobilized on a solid phase, to which an analyte binder is reversibly bonded via a reversible binding partner 2 that is bonded to the analyte binder, whereby the analyte binder is immobilized by binding between the reversible binding partners 1 and 2, b) Addition of the biological sample and binding of the analyte to the reversible immobilized analyte binder in the case that the biological sample contains the analytes, c) Separation of the biological sample, d) Addition of a dissolving buffer, which dissolves the binding between the reversible binding partners 1 and 2, whereby the binding of the analyte to the analyte binder remains optional, and e) Detection of the analyte in the dissolving buffer in the case that the biological sample contains the analytes and determination of the absence of the analyte in the case that the biological sample does not contain the analytes, respectively.
摘要翻译：本发明的主题是用于检测来自生物样品的分析物的方法，包括以下过程步骤：a）固定在固相上的可逆结合配偶体1的制备，分析物粘合剂通过可逆结合可逆地结合到其上配偶体2，其结合到分析物粘合剂上，由此通过可逆结合配偶体1和2之间的结合固定分析物粘合剂，b）添加生物样品并将分析物与可逆固定的分析物结合物结合，生物样品含有分析物，c）生物样品的分离，d）加入溶解缓冲液，其溶解可逆结合配偶体1和2之间的结合，由此分析物与分析物质粘合剂的结合仍然是可选的，e ）在生物样品含有分析物和确定不存在分析物的情况下，检测溶解缓冲液中的分析物在生物样品不分别含有分析物的情况下分析物。

5. 发明授权

US08524463B2 Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP 有权
标题翻译：通过CT-proET-1与NT-proBNP联合治疗急性冠状动脉综合征的诊断和风险分类
公开(公告)号：US08524463B2
公开(公告)日：2013-09-03
申请号：US12520166
申请日：2007-12-22
申请人： Andreas Bergmann , Nils Morgenthaler , Jana Papassotiriou , Joachim Struck , Leong L. Ng
发明人： Andreas Bergmann , Nils Morgenthaler , Jana Papassotiriou , Joachim Struck , Leong L. Ng
IPC分类号： G01N31/00 , G01N33/53
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2800/324
摘要： The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-1) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP.
摘要翻译：本发明涉及用于急性冠状动脉综合征（ACS）的诊断和/或风险分类的方法，特别是用于急性心肌梗塞（AMI）和心绞痛（AP）和/或心肌梗塞后的方法，其中确定 C-末端内皮素（CT-proET-1）或其片段和部分肽与NT-proBNP组合进行。

6. 发明授权

US08465941B2 Procalcitonin-based diagnosis of infections or inflammatory diseases of the respiratory tract in a patient with heart failure 有权
标题翻译：基于降钙素原的诊断为心力衰竭患者呼吸道感染或炎症性疾病
公开(公告)号：US08465941B2
公开(公告)日：2013-06-18
申请号：US12443897
申请日：2007-10-01
申请人： Andreas Bergmann , Nils Morgenthaler , Jana Papassotiriou , Joachim Struck
发明人： Andreas Bergmann , Nils Morgenthaler , Jana Papassotiriou , Joachim Struck
IPC分类号： C12Q1/48
CPC分类号： G01N33/74 , G01N2333/585 , G01N2800/12 , G01N2800/325
摘要： The invention relates to a method for diagnosis of infections or inflammatory diseases of the airways and lungs with associated heart failure, wherein the marker procalcitonin or a partial sequence thereof is determined in a patient to be examined, in particular for classifying patients according to risk. The invention further relates to a diagnostic device and kit for carrying out the method.
摘要翻译：本发明涉及一种用于诊断具有相关心力衰竭的气道和肺的感染或炎性疾病的方法，其中在要检查的患者中确定标志物降钙素原或其部分序列，特别是根据风险对患者进行分类。本发明还涉及一种用于执行该方法的诊断装置和套件。

7. 发明授权

US08357944B2 Semiconductor substrate and methods for the production thereof 有权
标题翻译：半导体衬底及其制造方法
公开(公告)号：US08357944B2
公开(公告)日：2013-01-22
申请号：US12063382
申请日：2006-08-10
申请人： Christian Drabe , Alexander Wolter , Roger Steadman , Andreas Bergmann , Gereon Vogtmeier , Ralf Dorscheid
发明人： Christian Drabe , Alexander Wolter , Roger Steadman , Andreas Bergmann , Gereon Vogtmeier , Ralf Dorscheid
IPC分类号： H01L29/18
CPC分类号： H01L21/76898 , H01L23/481 , H01L27/14636 , H01L31/02005 , H01L2223/6622 , H01L2924/0002 , H01L2924/00012 , H01L2924/00
摘要： The invention relates to semiconductor substrates and methods for producing such semiconductor substrates. In this connection, it is the object of the invention to provide semiconductor substrates which can be produced more cost-effectively and with which a high arrangement density as well as good electrical conductivity and closed surfaces can be achieved. In accordance with the invention, an electrically conductive connection is guided from its front side through the substrate up to the rear side. The electrically conductive connection is completely surrounded from the outside. The insulator is formed by an opening which is filled with material. The inner wall is provided with a dielectric coating and/or filled with an electrically insulating or conductive material. The electrically conductive connection is formed with a further opening which is filled with an electrically conductive material and is arranged in the interior of the insulator. The openings are formed with step-free inner walls aligned orthogonally to the front side or tapering continuously in the direction of the rear side.
摘要翻译：本发明涉及半导体衬底及其制造方法。在这方面，本发明的目的是提供可以更经济有效地制造并且可以实现高排列密度以及良好导电性和封闭表面的半导体衬底。根据本发明，导电连接从其前侧通过基板被引导到后侧。导电连接从外部完全包围。绝缘体由填充有材料的开口形成。内壁设置有电介质涂层和/或填充有电绝缘或导电材料。导电连接形成有另外的开口，其填充有导电材料并且布置在绝缘体的内部。开口形成有与前侧正交对准或者在后侧方向连续地逐渐变细的无梯度内壁。

8. 发明授权

US08298784B2 In vitro procedure for diagnosis and early diagnosis of neurodegenerative diseases 有权
标题翻译：诊断和早期诊断神经变性疾病的体外方法
公开(公告)号：US08298784B2
公开(公告)日：2012-10-30
申请号：US12300747
申请日：2007-05-15
申请人： Andreas Bergmann , Andrea Ernst , Harald Hampel
发明人： Andreas Bergmann , Andrea Ernst , Harald Hampel
IPC分类号： G01N33/53 , G01N33/537 , G01N33/567
CPC分类号： G01N33/6896 , G01N2800/28
摘要： An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.
摘要翻译：一种用于检测和早期检测神经变性疾病，用于确定严重程度并评估患有主观或客观可检测的认知障碍的患者中神经生殖疾病的进展和预测神经生殖疾病的体外方法，通过确定选自利尿钠肽，特别是ANP的分析物的浓度，以及如果需要，BNP和/或CNP在患者的生物液体中的浓度，由此分析物的测定直接和/或间接地作为相关的测定由相互前肽产生的共肽，并且基于所测定的分析物的测量浓度，从而可以形成关于神经变性疾病或这种疾病典型的早期形式或疾病过程和/或成功地减轻或预防疾病的努力。

9. 发明申请

US20120188625A1 MICROMECHANICAL DEVICE WITH TEMPERATURE STABILIZATION AND METHOD FOR ADJUSTING A DEFINED TEMPERATURE OR A DEFINED TEMPERATURE COURSE ON A MICROMECHANICAL DEVICE 有权
标题翻译：具有温度稳定性的微生物装置和用于调节定义温度的方法或在微生物装置上定义的温度课程
公开(公告)号：US20120188625A1
公开(公告)日：2012-07-26
申请号：US13408151
申请日：2012-02-29
申请人： Thilo Sandner , Harald Schenk , Joerg Heber , Thomas Klose , Andreas Bergmann , Christian Gerwig , Thomas Knieling
发明人： Thilo Sandner , Harald Schenk , Joerg Heber , Thomas Klose , Andreas Bergmann , Christian Gerwig , Thomas Knieling
IPC分类号： G02B26/10 , H05B6/80 , B23K26/00 , H05B6/00 , H05B1/00
CPC分类号： G01J5/061 , G01J5/026 , G01J5/0809 , G02B7/008 , G02B26/0816
摘要： A micromechanical device includes a micromechanical functional structure and an electromagnetic radiation heating associated with the micromechanical functional structure, which is formed to cause a spatially and temporally defined temperature or a spatially and temporally defined temperature course in the micromechanical functional structure.
摘要翻译：微机械装置包括微机械功能结构和与微机械功能结构相关联的电磁辐射加热，其形成为在微机械功能结构中引起空间和时间上限定的温度或空间和时间上限定的温度过程。

10. 发明申请

US20120003672A1 IN VITRO-METHOD FOR THE DIAGNOSIS, PROGNOSIS, MONITORING AND THERAPY FOLLOW-UP OF DISORDERS ASSOCIATED WITH THE METABOLIC SYNDROME, A CARDIOVASCULAR DISEASE AND/OR INSULIN RESISTANCE 审中-公开
标题翻译：与代谢综合征，心血管疾病和/或胰岛素抵抗相关的疾病的诊断，预防，监测和治疗的后续方法
公开(公告)号：US20120003672A1
公开(公告)日：2012-01-05
申请号：US13126646
申请日：2009-10-29
申请人： Andreas Bergmann
发明人： Andreas Bergmann
IPC分类号： G01N33/53 , C12Q1/54 , G01N21/76
CPC分类号： G01N33/6893 , G01N2800/04 , G01N2800/32
摘要： The present invention relates to an in vitro-method for diagnosis, prognosis and/or monitoring/therapy follow-up of a disorder of the metabolic system and/or cardiovascular system and/or insulin resistance in a subject, comprising the determination of the relative level of one or more cardiovascular markers in a sample of a subject and the use of the determined relative level of said one or more cardiovascular peptides for the diagnosis, prognosis and/or monitoring/therapy follow-up of a disorder of the metabolic system and/or cardiovascular system and/or insulin resistance in said subject.
摘要翻译：本发明涉及用于诊断，预后和/或监测/治疗受试者代谢系统和/或心血管系统和/或胰岛素抵抗障碍的随机化的体外方法，包括确定相对水平的受试者样品中的一种或多种心血管标志物，以及使用所确定的所述一种或多种心血管肽相对水平用于代谢系统病症的诊断，预后和/或监测/治疗随访，以及 /或所述受试者的心血管系统和/或胰岛素抵抗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式